SINGAPORE – Singapore is reviewing local and international safety data on vaccinating people with a history of anaphylaxis, or allergic reaction to food and medicines, with a view to allowing this group to receive mRNA Covid-19 jabs.
In a statement yesterday, the republic’s Covid-19 Vaccination Expert Committee said it intends to complete the review in two weeks.
Given the local and international data gathered, the panel said it recommends that the medical eligibility for the Pfizer-BioNTech or Moderna vaccine be expanded.
The committee has recommended extending the use of both brands’ jabs to previously restricted population sub-groups, namely Pregnancy and Breastfeeding, as well as Cancer Patients on Treatment.
With the international data being assuring, it has also determined that it is safe for people with a history of severe cutaneous adverse reactions (SCAR) to be vaccinated against the coronavirus.
This group was previously contraindicated against the Pfizer-BioNTech and Moderna vaccines out of an abundance of caution.
SCAR includes Stevens-Johnson syndrome, toxic epidermal necrolysis, drug rash with eosinophilia and systemic symptoms, and drug-induced hypersensitivity syndrome. – Bernama, June 1, 2021
